Modeling a lethal prostate cancer variant with small-cell carcinoma features. - Wikidata - wikimedia - TriplyDB

Modeling a lethal prostate cancer variant with small-cell carcinoma features.

Modeling a lethal prostate cancer variant with small-cell carcinoma features.

http://www.wikidata.org/entity/Q37582049

about

Molecular aspects of prostate cancer with neuroendocrine differentiation The many faces of neuroendocrine differentiation in prostate cancer progression Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer Aggressive variants of castration-resistant prostate cancer Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer.High expression of ubiquitin-conjugating enzyme 2C (UBE2C) correlates with nasopharyngeal carcinoma progression.Tenfibgen-DMAT Nanocapsule Delivers CK2 Inhibitor DMAT to Prostate Cancer Xenograft Tumors Causing Inhibition of Cell Proliferation.Neuroendocrine Tumors of the Prostate: Emerging Insights from Molecular Data and Updates to the 2016 World Health Organization Classification.Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.Stem cell and neurogenic gene-expression profiles link prostate basal cells to aggressive prostate cancer.Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers.Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas.Platinum-based chemotherapy for variant castrate-resistant prostate cancer.Experimental evidence of persistent androgen-receptor-dependency in castration-resistant prostate cancer.Targeting cell cycle and hormone receptor pathways in cancer.Castrate-resistant prostate cancer: postdocetaxel management Small cell carcinoma of the prostate.Androgen receptor splice variants in the era of enzalutamide and abiraterone.Neuroendocrine differentiation of prostate cancer: a review.Targeting neuroendocrine prostate cancer: molecular and clinical perspectives.Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma.Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers.The importance of regulatory ubiquitination in cancer and metastasis.Emerging Variants of Castration-Resistant Prostate Cancer.Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas.Characterization of the genomic architecture and mutational spectrum of a small cell prostate carcinoma Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties [Novel preclinical models and biomarkers for prostate cancer].TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup.Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer.Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling.Immunotherapy for Prostate Cancer: Where We Are Headed.Current perspectives on bone metastases in castrate-resistant prostate cancer.UBE2C Is a Transcriptional Target of the Cell Cycle Regulator FOXM1.Prostatic cancers: understanding their molecular pathology and the 2016 WHO classification.Function of Tumor Suppressors in Resistance to Antiandrogen Therapy and Luminal Epithelial Plasticity of Aggressive Variant Neuroendocrine Prostate Cancers.GABA promotes gastrin-releasing peptide secretion in NE/NE-like cells: Contribution to prostate cancer progression.Looking beyond Androgen Receptor Signaling in the Treatment of Advanced Prostate Cancer

P2860

Q26752910-3FD067C2-698F-46DF-99D8-50AB3DF185C6 Q26992049-1728746B-F0A3-4115-98E9-27AAE789595A Q27024775-4E1149AB-BC12-4F92-995E-194D2FCA07D6 Q33693256-C5719486-18BF-4526-BF75-3C5E9D5BB272 Q34055827-4C3C0518-03B6-4F42-AA27-4D0023862012 Q34669229-C9EC7B39-5F19-4E91-89A3-B0D37C791654 Q35423247-FAF5278B-8A6B-4614-BF80-70CD1C2CB622 Q35925835-C4204582-8465-4BC1-AA85-DF284FC89A24 Q36436763-8257DF79-FD5D-462C-AC32-7C4F0D6843CF Q36637412-07485FDE-0644-49FC-8F83-94470D2312BB Q36782301-897C1425-5A65-4443-A1A5-36EBBB12D774 Q36862668-F30EAAEE-C0A3-409E-956C-EDE216E9FDBB Q36977870-D0238F04-E970-456A-9BE7-92ACE9919B41 Q37139070-B4BC3858-1751-462C-95BA-B5D5A914691F Q37502364-FB567059-CDE4-4E23-AE53-F7311435C02C Q38076273-C6730D80-B765-4F1B-95B8-B145523ACEFE Q38188869-248E8034-2E17-4DC7-BC95-3CFD98D9E147 Q38232413-C0A34911-41EF-4952-A902-9050A7857442 Q38326554-A686C43A-72D8-4FA9-9C16-DE27906D9710 Q38362686-E1D9F7BD-6809-4919-A976-F2B982A5E5A6 Q38923020-68920D16-00FB-4704-B1E6-3EC270E68B9F Q39044979-6EAB996F-83FC-4E54-A38D-12C1B52DE93F Q39051337-696BF2EB-3E8B-4BB4-B8CE-7FFDBD17EBE3 Q39122602-97ECC423-5EEC-4698-8923-178967D8AF31 Q39210257-35726301-2760-4353-8CDA-8A97481AE9F3 Q40656134-0B63F521-67BF-4AB7-8172-9F79E0B715E0 Q41873815-5341314F-3F70-401B-8E68-7A4942AADC62 Q42078200-F5F4E719-E46C-4C95-81D0-F42ECCB3E7ED Q44582971-A8712984-5B5D-40FA-A485-D05ACB774FF7 Q46838481-8294C049-B104-4515-BA93-77B2F5395677 Q47140347-30D83028-2C37-4AF6-BBA1-93F2EA4D3005 Q47595568-8B8B7BD5-BCCB-4F7C-BDC5-31E97D178353 Q47670505-2E4EC999-D36E-42CC-9EFF-21B94905107E Q48176349-B93B1B58-6610-40E3-BECF-D4399BFFC914 Q49285273-3BD4E66F-CBF5-4A6C-9E61-D1494A20C971 Q52338003-776BB0C9-2A97-4834-BE5E-AC37A44A9A51 Q52629153-EC21FCBC-2ED1-4137-9C9E-45A4A8452558 Q53700061-193F8783-0372-46E6-A0BC-DBBC9A91908E Q55606621-ECA43F2B-B4FF-4791-9FC2-FA9DD8B36003 Q59051399-329E8EFB-63ED-440E-A391-C88FED9C2B2B

P2860

Modeling a lethal prostate cancer variant with small-cell carcinoma features.

http://www.wikidata.org/entity/Q37582049

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 12 December 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Modeling a lethal prostate cancer variant with small-cell carcinoma features.

@en

Modeling a lethal prostate cancer variant with small-cell carcinoma features.

@nl

type

label

Modeling a lethal prostate cancer variant with small-cell carcinoma features.

@en

Modeling a lethal prostate cancer variant with small-cell carcinoma features.

@nl

prefLabel

Modeling a lethal prostate cancer variant with small-cell carcinoma features.

@en

Modeling a lethal prostate cancer variant with small-cell carcinoma features.

@nl

P1433

Q37582049-6432D8D1-2A07-4949-8907-CBB758E39A95

P1476

Q37582049-96CC0264-692C-475B-BDFC-B9B67A45A913

P2093

Q37582049-047460AD-865E-49FE-86EC-65A5EA8ACA5B

Q37582049-4A653F37-31FE-4D46-811B-A39C66356383

Q37582049-745EC5E4-0022-4D00-B5D3-DE0229E2517F

Q37582049-78494A99-FE9F-44D4-8D67-65F0822ED86A

Q37582049-7E2B6124-AAD2-4A89-8878-9B3B451C8687

Q37582049-A1D683FE-9943-4BAF-8A64-1C1F240044E1

Q37582049-A8EF0033-438C-4DC2-896A-95FF597D544D

Q37582049-B07449F8-520F-4CEE-B1F6-2A15473E5D96

Q37582049-C6E9EF70-CE57-40F2-BC36-5945E8C9D862

Q37582049-C7EA0933-EA90-475F-9A42-74EE48BD0EED

P2860

Q37582049-000905C0-670B-4B1F-A008-5104CDFFA4AC

Q37582049-00FAA938-F04E-414B-B8B5-1CC2201896D7

Q37582049-01B9E33A-1B20-4872-AC0C-FE0CB6883549

Q37582049-0BF0DB92-6B0B-4C3E-8B60-70F019DD9451

Q37582049-0D959C0B-1572-4A14-8127-09F8361E5ABF

Q37582049-0F414A97-2493-4938-86C3-14D36FEFCD16

Q37582049-1192206A-8FA5-4C64-B42E-ACAFAA367275

Q37582049-1355B1DB-C0E4-4E16-A017-3EA38BDF7951

Q37582049-15C4982C-DD4C-4459-BFA1-FB7883F0B79F

Q37582049-18F8B9D1-5827-4A62-AAAA-3AB5989DB256

P304

Q37582049-5F2CC48A-90F7-45C4-96D1-87C3DC043946

P31

Q37582049-1BF818FA-47DE-4F75-9240-AB870D158516

P356

Q37582049-6DBCAE38-D374-46E5-A4DE-16F97B899A3D

P407

Q37582049-6AC30DC4-1C78-4CF9-8296-E05052E86CF9

P433

Q37582049-9D615927-BF80-4843-916A-2775D1CA8CF1

P478

Q37582049-AF43D481-2823-4D46-BF01-99D6425D7EE9

P577

Q37582049-B8591BDB-9051-425C-9252-5F5CAEADDA10

P698

Q37582049-2987324C-3A55-45A7-A5CC-D0B110F8115F

P932

Q37582049-CB034FD8-211E-4C23-A079-5BDB4AF879F1

P356

1078-0432.CCR-11-1867

P1433

Clinical Cancer Research

P1476

Modeling a lethal prostate cancer variant with small-cell carcinoma features.

@en

P2093

Ana M Aparicio

http://www.w3.org/2001/XMLSchema#string

Anh Hoang

http://www.w3.org/2001/XMLSchema#string

Brittany Kleb

http://www.w3.org/2001/XMLSchema#string

Christopher J Logothetis

http://www.w3.org/2001/XMLSchema#string

Eleni Efstathiou

http://www.w3.org/2001/XMLSchema#string

Guanglin Wu

http://www.w3.org/2001/XMLSchema#string

Jiexin Zhang

http://www.w3.org/2001/XMLSchema#string

Jing-Fang Lu

http://www.w3.org/2001/XMLSchema#string

Kanishka Sircar

http://www.w3.org/2001/XMLSchema#string

Nora M Navone

http://www.w3.org/2001/XMLSchema#string

P2860

Cell cycle kinases as therapeutic targets for cancer

Integrative genomic profiling of human prostate cancer

Estimating the occurrence of false positives and false negatives in microarray studies by approximating and partitioning the empirical distribution of p-values.

Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate.

Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate.

Neuroendocrine differentiation in prostatic carcinoma.

Overexpression of the E2 ubiquitin-conjugating enzyme UbcH10 causes chromosome missegregation and tumor formation.

Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer.

Inhibition of cyclin D1 kinase activity is associated with E2F-mediated inhibition of cyclin D1 promoter activity through E2F and Sp1.

Recurrent prostate carcinoma presenting as omental large cell carcinoma with neuroendocrine differentiation and resulting in bowel obstruction.

P304

666-677

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-11-1867

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2011-12-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22156612

http://www.w3.org/2001/XMLSchema#string

P932

3923417

http://www.w3.org/2001/XMLSchema#string